BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:10 PM
Sep 08, 2008
 |  BC Extra  |  Company News

EC approves Velcade for previously untreated MM

Johnson & Johnson (NYSE:JNJ) said the EC approved Velcade bortezomib in combination with melphalan and prednisone to treat previously untreated multiple myeloma...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >